<DOC>
	<DOCNO>NCT00186875</DOCNO>
	<brief_summary>The main purpose study find well participant relapse refractory ALL respond treatment etoposide- teniposide-based induction chemotherapy regimen side effect . Primary Objectives : - To estimate response rate patient refractory relapse ALL . - To estimate survival rate patient refractory relapse ALL treat risk-directed therapy .</brief_summary>
	<brief_title>Therapy Pediatric Relapsed Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>In study , subject divide high-risk standard-risk subgroup accord length first remission , type early cancer cell ( T B-cell ) site site disease relapse . The remission induction phase ( begin phase therapy ) consist three block therapy . Block A feature daily IV low-dose etoposide combination cytarabine give continuous IV , weekly vincristine , daily dexamethasone . In block B , combination weekly PEG-asparaginase , vincristine , daily dexamethasone give . Block C combination high-dose methotrexate , high-dose cytarabine , teniposide . There two phase consolidation ( treatment phase induction therapy ) . Additional therapy give two consolidation phase . Continuation consist eight weekly cycle chemotherapy . Periodic intrathecal therapy ( medicine give spinal fluid ) give throughout treatment . Participants achieve remission ( absence leukemia ) consolidation offer enrollment St. Jude NKEHM protocol ( NK cell transplant ) . Hematopoietic stem cell transplant ( HSCT ) plan participant high risk disease . HSCT do accord current institutional practice . The duration chemotherapy one year patient extramedullary ( outside bone marrow ) relapse two year others . Exploratory objective include : - To determine prevalence MRD child undergo treatment relapse ALL compare result obtain child newly diagnose ALL . - To compare level MRD bone marrow peripheral blood concomitantly child undergo treatment relapse ALL . - To characterize gene expression profile leukemia cell time diagnosis relapse improve understand mechanism relapse development drug resistance . - To study whether pre-existing emerge development serum antibody asparaginase relate hypersensitivity reaction asparaginase patient relapse ALL . Detailed Description Treatment Plan : All patient receive remission induction . All high-risk patient offer HSCT perform suitable donor identify preferably MRD become negative . If donor refuse HSCT , continue receive chemotherapy . Standard-risk patient continue chemotherapy MRD negative induction , offer HSCT MRD &gt; 0.01 % Block C Induction . Those achieve morphological CR induction treat accord contingency plan . Block A ( 14 day ) Dexamethasone 5 mg/m2/day , day 1-14 Vincristine 1.5 mg/m2 ( max 2 mg ) , day 1 8 Etoposide 25 mg/m2 , day 1-14 Cytarabine 25 mg/m2 , day 1-14 All patient proceed Block B clinical condition permit . CNS prophylaxis ( IT MHA ) CNS-1 : At time relapse day 14 . CNS-2 3 : At time relapse , day 8 14 . Leucovorin : 5 mg/m2 ( 5 mg max dose ) PO , 24 30 hour IT MHA . Block B ( 15 day ) All patient proceed Block B immediately Block A clinically well . Dexamethasone 6 mg/m2 , Days 1-14 Vincristine 1.5 mg/m2 , day 1 8 PEG-Asparaginase 2500 units/m2 , day 1 , 8 15 CNS prophylaxis ( IT MHA ) : CNS-2 3 , necessary . - CNS-1 : IT MHA - CNS-2 3 : day 8 ( minimum 4 dos maximum 8 dos induction ) Leucovorin : 5 mg/m2 ( 5 mg max ) PO 24 30 hour IT MHA Block C ( 1 day ) All patient receive Block B proceed Block C WBC &gt; 1,000/microL , ANC &gt; 300/microL platelet &gt; 50,000 microL recovery Block B. Methotrexate 8 gm/m2 , day 1 Cytarabine 1 g/m2 least 24 h ITHMA , day 1 Teniposide 165 mg/m2 , day 1 CNS prophylaxis ( IT MHA ) : - CNS-1 : time BMA Block C - CNS-2 3 : day 1 8 ( These two dos IT MHA may omit patient negative CSF blast 3 precede CSF exam ) time BMA Block C ( regardless previous CSF status ) . Leucovorin : 5 mg/m2 ( 5 mg maximum dose ) PO 24 30 hour IT MHA Consolidation I This 4-week phase . It start WBC &gt; 1000/microL , ANC &gt; 500/microL platelet &gt; 50,000 /microL Week 1 : Dex day 1 , 2 , 3 , PEG , VCR , Mito day 4 Week 2 : Dex day 1 , 2 , 3 , PEG , VCR , day 4 Week 3 : Dex day 1 , 2 , 3 , PEG , VCR , Mito day 4 Week 4 : Dex day 1 , 2 , 3 , PEG , VCR , day 4 Dexamethasone 8 mg/m2/day , day 1-3 PEG-Asparaginase 2500 units/m2 IM , day 4 week Vincristine 2 mg/m2 ( max 2 mg ) , day 4 week Mitoxantrone 12 mg/m2 , day 4 week 1 3 Interim Continuation Week 1*† : etoposide 300 mg/m2 IV , 1 dose day 1 Cyclophosphamide 300 mg/m2 IV , 1 dose day 1 Week 2* : Methotrexate 40 mg/m2 IV , 1 dose day 1 6-mercaptopurine # 75 mg/m2 PO , Days 1 7 Week 3* : teniposide 150 mg/m2 IV , 1 dose day 1 Cytarabine 300 mg/m2 IV , 1 dose day 1 Week 4* : Dexamethasone§ 12 mg/m2/day PO , TID Days 1 5 Vinblastine 6 mg/m2 IV ( max 10 mg ) , 1 dose day 1 Consolidation II Week 1*† : etoposide 300 mg/m2 IV , 1 dose day 1 Cyclophosphamide 300 mg/m2 IV , 1 dose day 1 Week 2* : Methotrexate 40 mg/m2 IV , 1 dose day 1 6-mercaptopurine # 75 mg/m2 PO , Days 1 7 Week 3* : teniposide 150 mg/m2 IV , 1 dose day 1 Cytarabine 300 mg/m2 IV , 1 dose day 1 Week 4* : Dexamethasone§ 12 mg/m2/day PO , TID , Days 1 5 Vinblastine 6 mg/m2 IV ( max 10 mg ) , 1 dose day 1 Continuation Week 1*†¶ : etoposide 300 mg/m2 IV , 1 dose day 1 Cyclophosphamide 300 mg/m2 IV , 1 dose day 1 Week 2* : Methotrexate 40 mg/m2 IV , 1 dose day 1 6-mercaptopurine # 75 mg/m2 PO , QHS , Days 1 7 Week 3* : teniposide 150 mg/m2 IV , 1 dose day 1 Cytarabine 300 mg/m2 IV , 1 dose day 1 Week 4 : Dexamethasone§ 12 mg/m2/day PO , TID , Days 1 5 Vincristine§ 2 mg/m2 IV ( maximum 2mg ) , 1 dose day 1 Week 5*‡ : etoposide 300 mg/m2 IV , 1 dose day 1 Cyclophosphamide 300 mg/m2 IV , 1 dose day 1 Week 6* : Methotrexate 40 mg/m2 IV , 1 dose day 1 6-mercaptopurine # 75 mg/m2 PO , QHS , Days 1 7 Week 7* : teniposide 150 mg/m2 IV , 1 dose day 1 Cytarabine 300 mg/m2 IV , 1 dose day 1 Week 8* : Dexamethasone§ 12 mg/m2/day PO , TID , Days 1 5 Vinblastine 6 mg/m2 IV ( max 10 mg ) , 1 dose day 1 Plan Stem Cell Transplant Patients positive MRD ( high-risk standard-risk ) end induction high-risk patient regardless MRD eligible HSCT - All high-risk patient eligible HSCT . HSCT perform soon MRD become negative induction . If MRD become negative ( &lt; 0.01 % ) donor find , patient continue chemotherapy phase ( Consolidation I , Interim Continuation , etc ) suitable donor find . - Those persistent positive MRD ( &gt; 0.01 % ) Block C also eligible HSCT All standard-risk patient continue chemotherapy MRD negative ( &lt; 0.01 % ) induction . - If MRD positive ( &gt; 0.01 % ) Block C induction , become eligible HSCT . - Standard-risk patient response progressive disease Block A positive MRD ( &gt; 0.01 % ) Block B candidate HSCT . They re-evaluated Block C. If MRD Block C positive , follow plan . If MRD negative Block C , management discuss Transplant Service Contingency Plan Patients achieve morphological CR ( M1 marrow ) Induction If CR ( M1 marrow ) achieve Induction , patient proceed Consolidation I . If achieve CR Consolidation I , offer enrollment St. Jude NKHEM protocol offer alternative therapy . If achieve CR NKHEM , come treatment . Patients achieve CR positive MRD ( &gt; 0.01 % ) Block C induction : Become eligible HSCT . Up two course chemotherapy ( course 1 2 ) give attempt reduce MRD . They receive HSCT soon MRD become negative ( MRD may repeat every 2-4 week indicate ) . Standard-risk patient positive MRD ( &gt; 0.01 % ) Block B proceed Block C. Patients category become candidate HSCT , MRD become negative Block C , management discuss Transplant Service . Chemotherapy may administer reduce MRD prior HSCT . Patients transplant soon MRD become negative . Patients ( high-risk standard-risk ) achieve CR , positive MRD ( &gt; 0.01 % ) Block C Induction become eligible HSCT . Up two course chemotherapy ( course 1 2 ) give attempt reduce MRD . They receive HSCT soon MRD become negative . If MRD remain positive course 2 , , proceed HSCT discussion Transplant Service . Course 1 Give chemotherapy accord plan Consolidation I . Start immediately regardless CBC . BMA perform WBC &gt; 1000/microL , ANC &gt; 300/microL platelet &gt; 50,000/microL . If MRD negative , receive HSCT . Course 2 This course give MRD positive Course 1 . Patients offer enrollment St. Jude NKHEM protocol . If still MRD positive Course 2 , patient may receive Interim Continuation , Consolidation II , Continuation MRD become negative await HSCT .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Teniposide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria Childhood ALL first relapse OR first hematological relapse extramedullary relapse , OR attain complete remission frontline therapy , OR lymphoblastic leukemia first relapse . Patients must 21 year age young Informed consent explain signed parent/legal guardian . Exclusion Criteria Life expectancy le 8 week Patients mature B cell ALL</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoblastic</keyword>
	<keyword>Acute</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin 's</keyword>
</DOC>